Cerulean Pharma Company Profile (NASDAQ:CERU)

About Cerulean Pharma

Cerulean Pharma logoCerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CERU
  • CUSIP:
Key Metrics:
  • Previous Close: $1.41
  • 50 Day Moving Average: $0.98
  • 200 Day Moving Average: $1.07
  • 52-Week Range: $0.63 - $4.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.93
  • P/E Growth: 0.00
  • Market Cap: $36.49M
  • Outstanding Shares: 27,435,000
  • Beta: 2.07
Profitability:
  • Return on Equity: -141.78%
  • Return on Assets: -77.97%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 2.47%
  • Quick Ratio: 2.47%
Additional Links:
Companies Related to Cerulean Pharma:

Analyst Ratings

Consensus Ratings for Cerulean Pharma (NASDAQ:CERU) (?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $6.57 (386.77% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:CERU)
Show:
DateFirmActionRatingPrice TargetDetails
11/9/2016Canaccord GenuityReiterated RatingBuy$6.00View Rating Details
10/23/2016Roth CapitalReiterated RatingBuy$2.50View Rating Details
10/19/2016Leerink SwannReiterated RatingMarket Perform$1.50View Rating Details
8/30/2016Barclays PLCLower Price TargetOverweight$5.00 -> $2.00View Rating Details
8/18/2016WedbushDowngradeOutperform -> NeutralView Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
3/9/2016J P Morgan Chase & CoBoost Price TargetMarket Outperform$9.00 -> $16.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Cerulean Pharma (NASDAQ:CERU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.43)($0.37)ViewN/AView Earnings Details
3/19/2015($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014($0.36)($0.34)ViewN/AView Earnings Details
5/29/2014($3.52)($3.70)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerulean Pharma (NASDAQ:CERU)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $-1.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.38)($0.40)
Q2 20162($0.49)($0.48)($0.49)
Q3 20163($0.50)($0.38)($0.45)
Q4 20163($0.52)($0.39)($0.46)
Q1 20171($0.40)($0.40)($0.40)
Q2 20171($0.40)($0.40)($0.40)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerulean Pharma (NASDAQ:CERU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cerulean Pharma (NASDAQ:CERU)
Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 22.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cerulean Pharma (NASDAQ:CERU)
DateHeadline
News IconShares Worth Watching: Cerulean Pharma Inc. (NASDAQ:CERU ... - Rockville Register (NASDAQ:CERU)
rockvilleregister.com - February 21 at 2:40 PM
News IconAnalysts Peer Into Their Crystal Balls For Cerulean Pharma Inc. (NASDAQ:CERU): Where Is It headed? - Winfield Review (NASDAQ:CERU)
winfieldreview.com - February 21 at 2:40 PM
News IconCerulean Pharma Inc. (NASDAQ:CERU) Projected to Achieve EPS Of $-0.3 - Stock Observer (NASDAQ:CERU)
www.thestockobserver.com - February 20 at 11:53 AM
News IconWhat Does The Chart For Cerulean Pharma Inc. (CERU) Tell Us Presently? - NY Stock News (NASDAQ:CERU)
nystocknews.com - February 18 at 4:05 PM
investornewswire.com logoCerulean Pharma Inc. (NASDAQ:CERU) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:CERU)
www.investornewswire.com - February 18 at 4:05 PM
News IconStock Target Update on Cerulean Pharma Inc. (NASDAQ:CERU ... - Rockville Register (NASDAQ:CERU)
rockvilleregister.com - February 18 at 4:05 PM
News IconABR Of Cerulean Pharma Inc. (NASDAQ:CERU) Stock At 2.33 - Stock Observer (NASDAQ:CERU)
www.thestockobserver.com - February 16 at 4:21 PM
News IconForward Earnings Estimate of Cerulean Pharma Inc.(CERU) - Highland Mirror (NASDAQ:CERU)
www.highlandmirror.com - February 11 at 4:20 PM
News IconCerulean Pharma Inc. (NASDAQ:CERU) Stock ABR At 2.33 - Stock Observer (NASDAQ:CERU)
www.thestockobserver.com - February 8 at 3:22 AM
News IconWatch List: Cerulean Pharma Inc (NASDAQ:CERU) – Post Registrar - Post Registrar (NASDAQ:CERU)
postregistrar.com - February 8 at 3:22 AM
News IconEvermay Wealth Management Cuts Position in Pfizer (PFE) by $1942955 (NASDAQ:CERU)
ekosvoice.com - February 7 at 5:20 PM
4-traders.com logoCerulean #Pharma Inc (NASDAQ :CERU) Blasts Off on Strategic Options Talk (NASDAQ:CERU)
www.4-traders.com - February 6 at 9:18 PM
News IconIt Looks Like Tom Brady's Super Bowl Game Jersey Was STOLEN! (NASDAQ:CERU)
mundoaguaysaneamiento.net - February 6 at 4:15 PM
News IconStock Seesawing Amidst Rampant Activity: Cerulean Pharma Inc. (NASDAQ:CERU) (NASDAQ:CERU)
xboxonezone.com - February 6 at 4:15 PM
News IconThe Hanesbrands Inc. (HBI) Shares Sold by Capital Fund Management SA (NASDAQ:CERU)
prensariotiretail.com - February 5 at 9:16 PM
News IconCerulean Pharma Inc (NASDAQ:CERU) Blasts Off on Strategic Options Talk - The Oracle Dispatch (NASDAQ:CERU)
oracledispatch.com - February 4 at 4:19 PM
News IconFinancial Watchlist of Cerulean Pharma Inc. (NASDAQ:CERU) - The Newburgh Press (NASDAQ:CERU)
newburghpress.com - February 3 at 9:32 PM
News IconCerulean Pharma, Inc. (NASDAQ:CERU) Breaks Out to Five-Month Highs - Street Register (NASDAQ:CERU)
streetregister.com - February 3 at 9:32 PM
smarteranalyst.com logoCerulean Pharma Inc (CERU) Shares Keep Rising As Investors Prepare For A Buyer - Smarter Analyst (NASDAQ:CERU)
www.smarteranalyst.com - February 3 at 9:32 PM
News IconSingle molecule detection of proteins in single cells (NASDAQ:CERU)
www.news-medical.net - February 3 at 4:30 PM
News IconSinglepoint Inc (OTCMKTS:SING) Tests New 52-week Highs on Momentum-Filled Friday (NASDAQ:CERU)
streetregister.com - February 3 at 4:30 PM
smarteranalyst.com logoFriday’s Market Insights: Cerulean Pharma Inc (CERU), Pernix Therapeutics Holdings Inc (PTX) and GoPro Inc (GPRO) (NASDAQ:CERU)
www.smarteranalyst.com - February 3 at 4:30 PM
News IconLooking at Moving Averages for Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - February 2 at 4:29 PM
streetinsider.com logoCerulean Pharma (CERU) to Review of Strategic Alternatives - StreetInsider.com (NASDAQ:CERU)
www.streetinsider.com - February 2 at 4:29 PM
streetinsider.com logoCerulean Pharma (CERU) to Review of Strategic Alternatives (NASDAQ:CERU)
www.streetinsider.com - February 1 at 9:34 PM
reuters.com logoBRIEF-Cerulean announces review of strategic alternatives (NASDAQ:CERU)
www.reuters.com - February 1 at 4:29 PM
News IconCerulean reviews clinical assets, nanoparticle-drug conjugates (NASDAQ:CERU)
www.massdevice.com - February 1 at 4:29 PM
finance.yahoo.com logoCerulean Announces Review of Strategic Alternatives (NASDAQ:CERU)
finance.yahoo.com - February 1 at 4:29 PM
finance.yahoo.com logo8:01 am Cerulean Pharma announces that its Board is conducting a comprehensive review of strategic alternatives (shares halted) (NASDAQ:CERU)
finance.yahoo.com - February 1 at 4:29 PM
bizjournals.com logoWaltham-based cancer drug firm Cerulean Pharma may seek a buyer (NASDAQ:CERU)
www.bizjournals.com - February 1 at 4:29 PM
News IconWilliams %R Check on Shares of Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - February 1 at 6:38 AM
News IconChecking in on Signals for Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 27 at 10:51 PM
News IconWhat is the Sell-side Saying About Cerulean Pharma Inc. (NASDAQ:CERU)? - Aiken Advocate (NASDAQ:CERU)
aikenadvocate.com - January 26 at 10:10 PM
News IconWatching the Technicals on Shares of Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 26 at 5:08 PM
News IconTechnical Action Update on Shares of Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 26 at 5:08 PM
News IconEarnings in Full Force, Analysts Take Aim at Cerulean Pharma Inc. (NASDAQ:CERU) - Wall Street Beacon (NASDAQ:CERU)
wsbeacon.com - January 26 at 5:08 PM
News IconFocus on RSI and CCI Levels: Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 20 at 10:24 PM
News IconWill This Stock Move with Earnings? The Sell-side chimes in on Cerulean Pharma Inc. (NASDAQ:CERU) Shares - Aiken Advocate (NASDAQ:CERU)
aikenadvocate.com - January 20 at 3:29 AM
News IconIndicator Level Review for Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 20 at 3:29 AM
News IconRisky Play or Bargain? Update on Cerulean Pharma Inc. (NASDAQ ... - Prospect Journal (NASDAQ:CERU)
prospectjournal.com - January 20 at 3:29 AM
News IconCerulean Pharma Inc CERU Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CERU)
www.bioportfolio.com - January 19 at 1:57 AM
News IconCan This Stock Pick Up Any Momentum: Cerulean Pharma Inc. (NASDAQ:CERU) - Prospect Journal (NASDAQ:CERU)
prospectjournal.com - January 18 at 8:56 PM
News IconWatching ADX Levels for Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 18 at 3:39 PM
News IconPlacing This Stock in the Hotbed: Cerulean Pharma Inc. (NASDAQ:CERU) - Prospect Journal (NASDAQ:CERU)
prospectjournal.com - January 18 at 3:02 AM
News IconSpot-check on CCI and RSI for Cerulean Pharma Inc. (CERU) - Sherwood Daily (NASDAQ:CERU)
sherwooddaily.com - January 17 at 10:01 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Cerulean ... - Wall Street Beacon (NASDAQ:CERU)
wsbeacon.com - January 15 at 4:07 PM
News IconCerulean Pharma Inc. (NASDAQ:CERU) Projected to Achieve EPS Of $-0.36 - Stock Observer (NASDAQ:CERU)
www.thestockobserver.com - January 15 at 4:07 PM
investornewswire.com logoSentiments And Ratings Alert: Cerulean Pharma Inc. (NASDAQ:CERU) - Investor Newswire (NASDAQ:CERU)
www.investornewswire.com - January 12 at 4:36 PM
News IconNotable Analysts Assessment of Stocks: Cerulean Pharma Inc., Continental Resources Inc - MMA Ring Report (NASDAQ:CERU)
mmaringreport.com - January 11 at 2:57 AM
News IconA Look at this Riveting Stock: Cerulean Pharma Inc. (NASDAQ:CERU) - Prospect Journal (NASDAQ:CERU)
prospectjournal.com - January 10 at 4:54 PM

Social

What is Cerulean Pharma's stock symbol?

Cerulean Pharma trades on the NASDAQ under the ticker symbol "CERU."

Where is Cerulean Pharma's stock going? Where will Cerulean Pharma's stock price be in 2017?

8 brokers have issued 1 year price targets for Cerulean Pharma's stock. Their forecasts range from $1.50 to $16.00. On average, they expect Cerulean Pharma's stock price to reach $6.57 in the next twelve months.

When will Cerulean Pharma announce their earnings?

Cerulean Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

How do I buy Cerulean Pharma stock?

Shares of Cerulean Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cerulean Pharma stock cost?

One share of Cerulean Pharma stock can currently be purchased for approximately $1.35.

Cerulean Pharma (NASDAQ:CERU) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cerulean Pharma (NASDAQ:CERU)

Earnings History Chart

Earnings by Quarter for Cerulean Pharma (NASDAQ:CERU)

Dividend History Chart

Dividend Payments by Quarter for Cerulean Pharma (NASDAQ:CERU)

Last Updated on 2/22/2017 by MarketBeat.com Staff